XML 112 R76.htm IDEA: XBRL DOCUMENT
v3.22.4

Collaborative Arrangements and Licensing Agreements, Metagenomi License Agreement (Details) - Metagenomi License Agreement [Member] $ in Millions | 3 Months Ended |
--- | --- | ---
Dec. 31, 2022 USD ($) | Nov. 30, 2022 Target
Collaborative Arrangement and Licensing Agreement [Abstract] |  |
Payment to license intellectual property | $ | $ 80 |
Research and development expense | $ | $ 80 |
Maximum [Member] |  |
Collaborative Arrangement and Licensing Agreement [Abstract] |  |
Number of targets to be researched, developed and commercialized | Target |  | 4
Number of additional targets to be researched, developed and commercialized | Target |  | 4

X
- References No definition available. + Details
Name: | ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of additional targets to be researched, developed and commercialized under the collaboration agreement upon achievement of certain development milestones. + References No definition available. + Details
Name: | ions_NumberOfAdditionalTargetsToBeResearchedDevelopedAndCommercialized
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of targets to be researched, developed and commercialized under the collaboration agreement. + References No definition available. + Details
Name: | ions_NumberOfTargetsToBeResearchedDevelopedAndCommercialized
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow to license intellectual property under a collaboration and license agreement. + References No definition available. + Details
Name: | ions_PaymentToLicenseIntellectualProperty
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_MetagenomiCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |